Efficacy of roflumilast in the COPD frequent exacerbator phenotype

Chest

Volumn 143, Issue 5, 2013, Pages 1302-1311

  Wedzicha, Jadwiga A ^a   Rabe, Klaus F ^c,d,f   Martinez, Fernando J ^g   Bredenbrok̈er, Dirk ^e   Brose, Manja ^e   Goehring, Udo Michael ^e   Calverley, Peter M A ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^c UNIVERSITY OF KIEL   (Germany)

^d Center for Pulmonology and Thoracic Surgery   (United Kingdom)

^e Nycomed A Takeda Company   (Germany)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; ROFLUMILAST;

AIRWAY OBSTRUCTION; ARTICLE; BACKACHE; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEATH; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DYSPNEA; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMAN; HYPERTENSION; INFLUENZA; MULTICENTER STUDY (TOPIC); NAUSEA; PERIPHERAL EDEMA; PNEUMONIA; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION;

EID: 84877589288     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-1489     Document Type: Article

References (26)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of COPD. 2011. Global Initiative for Chronic Obstructive Lung Disease website. http://www.goldcopd.org/ Guidelines/guidelines-resources.html. Accessed March 27, 2013.
2. World Health Organization. Chronic Obstructive Pulmonary Disease Fact Sheet. 2012. World Health Organization website. http://www.who.int/mediacentre/ factsheets/fs315/en/index.html. Accessed November 20, 2012.
3. Celli BR, Macnee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper [published correction appears in Eur Respir J. 2006;27(1):242]. Eur Respir J. 2004;23(6):932-946. (Pubitemid 38807371)
4. Perera WR, Hurst JR, Wilkinson TM, et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J. 2007;29(3):527-534. (Pubitemid 46372101)
5. Donaldson GC, Seemungal TA, Patel IS, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005;128(4):1995-2004. (Pubitemid 41507533)
6. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55(2):114-120. (Pubitemid 30245950)
7. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128-1138.
8. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847-852. (Pubitemid 35178607)
9. Donaldson GC, Wilkinson TMA, Hurst JR, Perera WR, Wedzicha JA. Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171(5):446-452. (Pubitemid 40444244)
10. Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5 pt 1):1418-1422.
11. Miravitlles M, Ferrer M, Pont A, et al IMPAC Study Group. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax. 2004;59(5):387-395. (Pubitemid 38624744)
12. Soler-Cataluña JJ, Martínez-García MÁ, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925-931. (Pubitemid 41598207)
13. Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials [published correction appears in Lancet. 2010;376(9747):1146]. Lancet. 2009;374(9691):685-694.
14. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al; M2-127 and M2-128 study groups. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009;374(9691):695-703.
15. Bateman ED, Rabe KF, Calverley PM, et al. Roflumilast with long-acting b 2 -agonists for COPD: influence of exacerbation history. Eur Respir J. 2011;38(3):553-560.
16. Rennard SI, Calverley PM, Goehring UM, Bredenbröker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD. Respir Res. 2011;12:18.
17. Grootendorst DC, Gauw SA, Verhoosel RM, et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax. 2007;62(12):1081-1087. (Pubitemid 350206202)
18. Hatzelmann A, Morcillo EJ, Lungarella G, et al. The preclinical pharmacology of roflumilast-a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2010;23(4):235-256.
19. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ; M2-124 and M2-125 study groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009;374(9691):685-694.
20. Postma D, Anzueto A, Calverley P, et al. A new perspective on optimal care for patients with COPD. Prim Care Respir J. 2011;20(2):205-209.
21. Rabe KF, Wedzicha JA. Controversies in treatment of chronic obstructive pulmonary disease. Lancet. 2011;378(9795):1038-1047.
22. Agustí A, Vestbo J. Current controversies and future perspectives in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;184(5):507-513.
23. Patel IS, Seemungal TAR, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax. 2002;57(9):759-764. (Pubitemid 34984972)
24. Restrepo MI, Mortensen EM, Pugh JA, Anzueto A. COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J. 2006;28(2):346-351. (Pubitemid 44914234)
25. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med. 2009;169(3):219-229.
26. Quint JK, Donaldson GC, Hurst JR, Goldring JJ, Seemungal TR, Wedzicha JA. Predictive accuracy of patient-reported exacerbation frequency in COPD. Eur Respir J. 2011;37(3):501-507.